A New AI-Powered Chapter for MedTech Leading Voice

MedTech Leading Voice | Issue 152

This week’s update centers on the launch of MLVX.ai, expanded expert searchability with the MLV100 2026 preview, and regulatory signals shaping documentation, CAPA, AI oversight, and standards activity across regions.

📝 From the Editor

As I mentioned in my post yesterday, we’ve entered a new AI-powered chapter for MedTech Leading Voice.

Last Friday’s soft launch of MLVX.ai brought more than 120 people together for a first look at a shared, expert-driven workspace for MedTech regulatory, quality, clinical, software, standards, and strategy questions.

🔥 Try MLVx.ai now for a sneak preview of the MLV100 2026!

The issue also highlights new standards activity, risk and documentation expectations, AI oversight, and emerging regulatory updates across multiple domains.

— Sean Smith, Publisher

🎯 Featured

Introducing MLVX.ai — Expert Knowledge, Searchable and On Demand

On lastFriday’s In-Focus call, Jose Bohorquez and I introduced MLVX.ai, a new AI-powered platform shaped by the guidance, transcripts, discussions, and shared knowledge of more than 100+ MedTech experts. Watch the replay >>

The core idea is simple:

What if you could ask a MedTech question and receive an answer grounded in real guidance, real source material, and the demonstrated expertise of identifiable contributors?

MLVX.ai provides:

• Answers backed by traceable references
• A unified workspace across RA, QA, clinical, software, HF, cybersecurity, and standards
• Clear attribution showing who said what and where it came from
• Expert profiles linked to real people and real work

🔥 As part of the rollout, the MLV100 for 2026 is now fully integrated into the platform, offering a searchable directory of recognized MedTech voices.

This launch marks the beginning of a shared learning infrastructure for the community.

Try MLVx Now >>

📌 This Week’s Top Posts (In no special order)

• Leo Eisner summarized the new IEC Draft Technical Specification on EMF exposure for MEE, explaining its purpose, comment timelines, and relevance for future 60601-1 Edition 4 architecture.
• Danny Van Roijen shared the EDPB Work Programme 2026–2027 and its key changes.
• The non-negotiables for understanding GSPRs 20–22, detailed in an article by Angelina Lisandrelli.
• Sigrid Berge van Rooijen discussed the hidden risks of AI scribes and the need for systemic guardrails.
• The latest EU MDR harmonized standards update and key revisions was explained by Stefano Bolletta.
• In her weekly Monday news, Marina Daineko highlighted regulatory layering, AI and CRA impact, and the tightening scrutiny on technical documentation.
• Georg Digel overviewed practical ways to strengthen and prepare for CAPA investigations.
• Changes to the New Zealand amended Regulation 44A and its impact on manufacturers, evaluated by Tibor Zechmeister. 
• Dr Hugh Harvey urged for the regulation of AI scribes as a medical device to reduce fabrication of patient medical histories and records. 
• The meaning of the unspoken inherent use claim by the FDA was defined and discussed by Michelle Lott.
• Bastian Krapinger-Ruether broke down 5 steps to evaluate if an AI-supported medical device is classified as high-risk under the AI Act. 
• Albrecht W. Frauendorf underscored how harmonized regulations and disciplined Stage-Gate development are redefining MedTech innovation in 2026.
• 376 FDA Class I recall trends and root causes from 2025, were revealed by Vanessa Rivel. 
• Medical Device Developments announced FDA approval for Medtronic’s integrated Stealth ASiS robotics system.
• An article on overcoming legacy documentation bottlenecks with AI-powered platform reuse, written by Laetitia H.

🗓️ Upcoming Events & Webinars

• Tuesday, February 24, 2026 | 10:00 AM ET / 4:00 PM CET — Global Human Factors Strategy for MedTech, featuring Jessica Parry (Senior Human Factors Consultant & Manager, Site Lead – UK, ClariMed) and Jenny Collinson (Director of Human Factors Strategy & Advisory, ClariMed), focused on human factors strategy across the U.S., EU, and UK. Register Now >>
• Thursday, February 26, 2026 | 10:00 AM ET / 4:00 PM CET — EU Regulatory Roadmap Part 2: Avoiding Liability Pitfalls, featuring Bassil Akra (CEO, AKRA TEAM) and Erik Vollebregt (Partner, Axon Lawyers), focused on liability exposure and risk management under EU MDR and IVDR. Register Now >>
• Friday, February 27, 2026 | 11:00 AM ET — The MedTech Employment Outlook for 2026, a Friday In-Focus session featuring Elena Kyria (Founder & CEO, Elemed), focused on how hiring, evaluation, and career signals are shifting in MedTech. Register with one click >>

💥 Weekly 510(k) Roundup

February 16, 2026 | From Marcus Engineering, LLC

74 total clearances across multiple categories, including 10 first-time clearances (🚀)

• Drägerwerk AG & Co KGaA — Babyleo TN500 (🚀): Cleared under General Hospital, the Babyleo TN500 integrates incubator and radiant warmer functions into a single neonatal platform, supporting stable environmental control for premature infants during critical early care.
• Boston Scientific Corporation — SpaceOAR Vue System: Cleared within Radiology, the SpaceOAR Vue hydrogel system provides a visualizable anatomical spacer during prostate radiotherapy, helping maintain separation between the prostate and surrounding structures to reduce unintended exposure.
• EDAN Instruments, Inc. — Holter ECG and ABP System: Cleared within Cardiovascular, this wearable device captures ambulatory ECG and blood pressure simultaneously, enabling synchronized analysis of rhythm and hemodynamic patterns during daily activity.

Explore the full list of this week’s clearances on the 510(k) Roundup page.

📋 Regulatory Roundup

February 16, 2026 Issue | By Martin King

This week’s regulatory activity reflects a high volume of global updates spanning pharmacovigilance, reliance pathways, GMP expectations, market-access policy, and the growing role of data, AI, and real-world evidence in regulatory decision-making. Authorities released new guidance and consultations across the 📌 European Medicines Agency (EMA), 📌 CIOMS, 📌 TGA, 📌 Egyptian Drug Authority, 📌 Health Canada, 📌 SAHPRA, 📌 ICH, 📌 HPRA, 📌 MHRA, 📌 Swissmedic, 📌 UK DHSC, and 📌 ANVISA.

Across regions, regulators strengthened safety-monitoring expectations, advanced reliance and harmonisation initiatives, increased GMP and submission requirements, updated market-access frameworks, and expanded programmes focused on real-world evidence, clinical-study data, and AI-related decision support. The combined direction underscores an increasing emphasis on lifecycle vigilance, coordinated oversight, and structured evidence generation.

Explore the Issue >>

In Case You Missed It

Tuesday, February 17, 2026 — ISO/DIS 18969: Introducing a Process-Based Approach to Clinical Evaluation, featuring Danielle Giroud (CEO, MD-CLINICALS SA, Chair of the ISO 18969 Working Group) and Maria E. Donawa, MD (Founder & President, Donawa Lifescience, Member of the ISO 18969 Working Group). Watch the replay >>

🔥 Postscript

More than 625 professionals have already registered for next Thursday's webinar:EU Regulatory Roadmap Part 2: Avoiding Liability Pitfalls, featuring Bassil Akra (CEO, AKRA TEAM) and Erik Vollebregt (Partner, Axon Lawyers), focused on liability exposure and risk management under EU MDR and IVDR. Register Now >>